The price of progress: Funding and financing Alzheimer's disease drug development

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 4 - Trang 330-343 - 2018
Jeffrey Cummings1, Carl Reiber2, Parvesh Kumar2
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
2University of Nevada, Las Vegas, NV, USA

Tóm tắt

AbstractIntroductionAdvancing research and treatment for Alzheimer's disease (AD) and the search for effective treatments depend on a complex financial ecosystem involving federal, state, industry, advocacy, venture capital, and philanthropy funding approaches.MethodsWe conducted an expert review of the literature pertaining to funding and financing of translational research and drug development for AD.ResultsThe federal government is the largest public funder of research in AD. The National Institute on Aging, National Institute of Mental Health, National Institute of General Medical Sciences, and National Center for Advancing Translational Science all fund aspects of research in AD drug development. Non‐National Institutes of Health federal funding comes from the National Science Foundation, Veterans Administration, Food and Drug Administration, and the Center for Medicare and Medicaid Services. Academic Medical Centers host much of the federally funded basic science research and are increasingly involved in drug development. Funding of the “Valley of Death” involves philanthropy and federal funding through small business programs and private equity from seed capital, angel investors, and venture capital companies. Advocacy groups fund both basic science and clinical trials. The Alzheimer Association is the advocacy organization with the largest research support portfolio relevant to AD drug development. Pharmaceutical companies are the largest supporters of biomedical research worldwide; companies are most interested in late stage de‐risked drugs. Drugs progressing into phase II and III are candidates for pharmaceutical industry support through licensing, mergers and acquisitions, and co‐development collaborations.DiscussionTogether, the funding and financing entities involved in supporting AD drug development comprise a complex, interactive, dynamic financial ecosystem. Funding source interaction is largely unstructured and available funding is insufficient to meet all demands for new therapies. Novel approaches to funding such as mega‐funds have been proposed and more integration of component parts would assist in accelerating drug development.

Tài liệu tham khảo

10.1016/j.jalz.2017.02.001 10.1016/j.jalz.2007.04.381 Alzheimer's Disease International, 2015, World Alzheimer's Report 2015: The Global Impact of Dementia 10.1016/j.jalz.2011.11.010 10.1016/j.cger.2013.07.003 10.1186/s13195-017-0283-5 10.1586/14737175.2015.995638 10.1186/alzrt269 Cummings J., 2016, Neurodegenerative Diseases: Unifying Principles 10.1002/ardp.201600078 Muller S., 2010, Open‐access public‐private partnerships to enable drug discovery–new approaches, IDrugs, 13, 175 10.1111/nyas.12417 10.1001/jamainternmed.2017.3601 10.1016/j.jhealeco.2016.01.012 10.1056/NEJMc1305541 10.1080/14737167.2017.1313118 Cywin C.L., 2017, National Institutes of Health Blueprint Neurotherapeutics Network: results to date and path forward, Neurotherapeutics, 14, 1066, 10.1007/s13311-017-0530-2 Thal L.J., 2004, The Alzheimer's disease cooperative study in 2004, Alzheimer Dis Assoc Disord, 18, 183 10.1016/j.jalz.2015.05.006 10.1016/j.jalz.2015.05.007 10.1016/j.jalz.2014.11.001 10.1038/nm.2222 Cummings J.L., 2016, Re‐engineering Alzheimer clinical trials: Global Alzheimer Platform Network, J Prevent Alz Dis, 3, 114 10.1016/j.neurobiolaging.2016.02.024 10.1371/journal.pgen.1001308 10.3233/JAD-2011-0059 Beekly D.L., 2004, The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database, Alzheimer Dis Assoc Disord, 18, 270 10.1097/WAD.0b013e3181c9983f 10.1517/14728222.2016.1135132 10.1126/scitranslmed.3001862 Institute of Medicine, 2013, The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research Colvis C.M., 2014, Innovation in therapeutics development at the NCATS, Neuropsychopharmacology, 39, 230, 10.1038/npp.2013.247 Gurwitz D., 2011, A deserving role for the National Center for Advancing Translational Sciences, Lancet, 377, 1745, 10.1016/S0140-6736(11)60729-0 10.1111/cts.12512 Becker G.J., 2005, The National Institute of General Medical Sciences, J Am Coll Radiol, 2, 790, 10.1016/j.jacr.2005.06.001 10.1097/ACM.0b013e31822225c5 Chapes S.K., 2013, Assessment of the Impact of the Kansas IDeA Network of Biomedical Research Excellence Program on Undergraduate Participation in Research, J Microbiol Biol Educ, 14, 47, 10.1128/jmbe.v14i1.492 Cummings J., 2014, The Cleveland Clinic Lou Ruvo Center for Brain Health: keeping memory alive, J Alzheimers Dis, 38, 103, 10.3233/JAD-130791 Ismail M.S., 2007, National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness‐ Alzheimer's Disease (CATIE‐AD): baseline characteristics, Curr Alzheimer Res, 4, 325, 10.2174/156720507781077214 10.1056/NEJMoa061240 10.1001/jama.2009.1913 Johnston S.C., 2015, Predictors of negotiated NIH indirect rates at US institutions, PLoS One, 10, e0121273, 10.1371/journal.pone.0121273 Bargmann C.I., 2014, The Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) initiative and neurology, JAMA Neurol, 71, 675, 10.1001/jamaneurol.2014.411 Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Working Group, 2013, Advisory Committee to the NIH Director Interim Report 10.1126/science.1239276 10.1002/cpt.16 10.1016/j.jalz.2014.11.005 10.1016/j.tim.2013.03.006 10.1016/j.drudis.2008.10.003 10.1186/1479-7364-7-5 10.1038/nrd4727 10.1001/jama.2017.2573 10.4155/fmc.15.111 10.1021/acschemneuro.7b00040 10.1517/13543776.2015.1040762 10.1080/13543776.2018.1409209 10.1038/nrd3462 10.1038/nrd3251 10.1056/NEJMra1510070 10.1056/NEJMsa1008268 Stossel T.P., 2007, Overregulation of conflicts hinders medical progress, Cleve Clin J Med, 74, S14, 10.3949/ccjm.74.Suppl_2.S14 10.1038/clpt.2010.29 Kim E.S., 2017, Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine, Drug Discov Today, 22, 1064, 10.1016/j.drudis.2017.03.015 10.1111/eci.12801 10.1002/jbmr.2881 Lawrence S., 2017, Biotech's wellspring‐a survey of the health of the private sector in 2016, Nat Biotechnol, 35, 413, 10.1038/nbt.3867 10.1377/hlthaff.2014.1051 Thomas D., 2015, Venture Funding of Therapeutic Innovation: A Comprehensive Look at a Decade of Venture Funding of Drug R&D Gates B., 2017, Why I'm digging deep into Alzheimer's 2017, Alzheimer's Association Annual Report: Fiscal Year 2016 10.1016/j.neurol.2013.07.017 10.1056/NEJMra1612575 Joyce C., 2014, Transforming our approach to translational neuroscience: the role and impact of charitable nonprofits in research, Neuron, 84, 526, 10.1016/j.neuron.2014.10.030 Bartek R.J., 2014, Foundation‐industry relationships–a new business model joint‐venture philanthropy in therapy development, Curr Top Med Chem, 14, 313, 10.2174/1568026613666131127154903 Milken Institute Philanthropy Advisory Service.Alzheimer's Disease: A Giving Smarter Guide to Accelerate Development of New Therapies.2015 Pharmaceutical Research and Manufacturers of America.Biopharmaceutical Research Industry Profile Washington DC2017 Cummings J., 2017, Alzheimer's disease drug development pipeline: 2017, Alzheimer's Dement, 3, 367, 10.1016/j.trci.2017.05.002 10.1186/alzrt86 10.1016/j.neurobiolaging.2012.02.027 10.1016/j.neures.2016.11.003 10.1016/j.drudis.2013.01.012 10.1126/scitranslmed.3008228 Montazerhodjat V., 2016, Financing drug discovery via dynamic leverage, Drug Discov Today, 21, 410, 10.1016/j.drudis.2015.12.004 10.2174/1568026613666131127155703 10.1016/j.neuron.2014.10.006 10.1038/nrd4230 10.1016/j.drudis.2014.06.019 Carter A.J., 2017, Establishing a reliable framework for harnessing the creative power of the scientific crowd, PLoS Biol, 15, e2001387, 10.1371/journal.pbio.2001387 10.1186/s12961-017-0237-1 10.1111/cts.12444 10.1007/s40266-016-0406-x
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 4

330-343

Thông tin tác giả